aspirin has been researched along with cardiovascular agents in 283 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (4.95) | 18.7374 |
| 1990's | 30 (10.60) | 18.2507 |
| 2000's | 83 (29.33) | 29.6817 |
| 2010's | 140 (49.47) | 24.3611 |
| 2020's | 16 (5.65) | 2.80 |
| Authors | Studies |
|---|---|
| Sleight, P | 1 |
| Amanullah, AM; Lindvall, K | 1 |
| Braunwald, E; Hamm, P; Lamas, GA; Pfeffer, MA; Rouleau, JL; Wertheimer, J | 1 |
| Grunfeld, S; Han, E; Joseph, R; Tsering, C; Welch, KM | 1 |
| Boissel, JP; Diaz, N; Gillet, J; Némoz, C; Salewski, B | 1 |
| Addonizio, VP; Berkowitz, HD; Cottrell, ED; Ellison, N; Fisher, CA; Kappa, JR; Sobel, M | 1 |
| Bekemeier, H; Hirschelmann, R | 1 |
| Bertelé, V; de Gaetano, G; del Rosso, G; Libretti, A; Mussoni, L; Pintucci, G; Romano, G | 1 |
| Fischer, W; Hanselle, U; Huhmann, W; Schulz, V; Zietsch, V | 1 |
| Morishima, Y; Shibano, T; Shibutani, T; Takahashi, M; Tanaka, T; Watanabe, K | 1 |
| Gysling, E | 1 |
| Abendschein, DR; Meng, YY; Ryan, US; Trachtenburg, J | 1 |
| Bakran, I; Francetic, I; Giljanovic, S; Huic, M; Mucolic, V; Vrhovac, B | 1 |
| Loscalzo, J; Rabbani, LE | 1 |
| Burr, RL; Cain, KC; Cowan, MJ; Narayanan, SB; Pike, K | 1 |
| Lasserre, B; Périat, M | 1 |
| Bode, C; Katus, HA; Scheffold, T | 1 |
| Castro, P; Corbalán, R; Kunstmann, S; Vergara, I | 1 |
| Rich, MW | 1 |
| Aronow, WS; Forman, R | 1 |
| Cottier, C | 1 |
| Kala, R | 1 |
| Aronowski, J; Grotta, JC; Strong, R | 1 |
| Heinz, M; Söhngen, M; Theiss, W; van de Flierdt, E | 1 |
| Heller, RF; Lim, LL; Tesfay, GM | 1 |
| Brotons, C; Calvo, F; Cascant, P; Moral, I; Permanyer-Miralda, G; Ribera, A | 1 |
| Goldberg, RJ; Gore, JM; Gurwitz, JH; McCormick, D; Savageau, J; Yarzebski, J | 1 |
| Petticrew, M; Sheldon, T; Turner-Boutle, M | 1 |
| Cornell, ES; Heckbert, SR; Psaty, BM; Smith, NL; Tracy, RP | 1 |
| Ferguson, JJ | 1 |
| Dietz, R; Monti, J; Willenbrock, R | 1 |
| Chahal, PS; Longhurst, JC; Rendig, SV | 1 |
| Carrier, M; Daly, P; Davies, R; Gudas, V; Kostuk, W; Latter, D; Rivard, M; Sullivan, J; Teo, K; White, M | 1 |
| Kim, EK; Lee, JR; Seo, JW; Yang, JH | 1 |
| Hovland, A; Nielsen, EW | 1 |
| Ahn, YK; Bae, Y; Cho, JG; Cho, JH; Jeong, MH; Kang, JC; Kang, KT; Kim, KH; Kim, NH; Kim, SH; Lee, SH; Park, JC; Rhew, JY | 1 |
| Haghiac, M; Hilderman, RH; Pojoga, LH | 1 |
| Kreuzer, J; Kübler, W | 1 |
| Beckey, NP; Geber, J; Korman, L; Parra, D | 1 |
| Kiberd, BA | 1 |
| Bobrie, G; La Batida Alanore, A; Plouin, PF; Rossignol, P; Roueff, S | 1 |
| Hohmann, C; Jaster, M; Kühl, U; Pauschinger, M; Rauch, U; Schultheiss, HP; Schwimmbeck, PL; Weikert, U | 1 |
| Kolbasov, SE; Kovalenko, AL; Lychakov, AV; Savateeva, TN; Shevchuk, MK | 1 |
| Armstrong, PW; Borer, J; Lorell, BH; Nissen, S | 1 |
| Chirkov, YY; Holmes, AS; Horowitz, JD; Stewart, S; Willoughby, SR | 1 |
| Cieśliński, A; Grajek, S; Grygier, M; Mularek-Kubzdela, T; Seniuk, W | 1 |
| Aronow, WS; Koneru, S; Nayak, D; Pucillo, AL; Woodworth, S | 1 |
| Czuriga, I | 1 |
| Edwards, R; Heller, RF; McElduff, P | 1 |
| Radley, DC; Stafford, RS | 1 |
| Aguilar, JC; Cleland, J; Cohen-Solal, A; Dietz, R; Eastaugh, J; Follath, F; Freemantle, N; Gavazzi, A; Hobbs, R; Komajda, M; Korewicki, J; Madeira, HC; Mason, J; Moiseyev, VS; Preda, I; Swedberg, K; Van Gilst, WH; Widimsky, J | 1 |
| Aursnes, I; Kvan, E; Reikvam, A | 1 |
| Bennett, KE; Feely, J; Williams, D | 1 |
| Abbott, KC; Agodoa, LY; Bakris, GL; Taylor, AJ; Trespalacios, FC | 1 |
| Brieger, D; Brown, DL; Deligonul, U; Duerr, R; Eisenberg, MJ; Goudreau, E; Huynh, T; Lefkovits, J; Mak, KH; Okrainec, K; Pilote, L; Sedlis, S; Tsang, J | 1 |
| DEL PINAL, JL; DOSAL, AF | 1 |
| LECCA, GG | 1 |
| MANNETTI, C; PAVERO, A; SOLARI, S | 1 |
| FLEURY, C; FROMMEL, E; SCHMIDT-GINZKEY, J | 1 |
| BURLESON, T; OWENS, RE | 1 |
| FRIEDMAN, AP | 1 |
| MONCKTON, G | 1 |
| CHEVAL, P; HENNION, M; LEBEURRE, R; VERHAEGHE, A | 1 |
| KURIAKI, K; MARUMO, H | 1 |
| Armstrong, PW; Ezekowitz, J; McAlister, FA; Tonelli, M | 1 |
| Banerjee, S; Denniston, AK; Dodson, PM; Gibson, JM | 1 |
| Schrör, K | 1 |
| Hofmann, T | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Daida, H; Kurata, T; Miyauchi, K; Okazaki, S; Sato, H; Shimada, K; Yokoyama, T | 1 |
| Capewell, S; Critchley, J; Liu, J; Wei, W; Zhao, D | 1 |
| Beygui, F; Blanchet, B; Choussat, R; Collet, JP; Golmard, JL; Metzger, JP; Montalescot, G; Payot, L; Tanguy, ML; Thomas, D; Vignolles, N | 1 |
| Ezekowitz, J; Ghali, WA; Humphries, KH; Knudtson, ML; McAlister, FA; Norris, CM; Tonelli, M | 1 |
| Kopff, A; Kopff, M; Kowalczyk, E | 1 |
| Batyraliev, TA; Kiktëv, VG; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA | 1 |
| Aude, YW; Bansal, D; Bissett, J; Fahdi, I; Gaddam, V; Garza, L; Joseph, J; Mehta, JL; Molavi, B; Pai, BV; Sinha, A; Smith, ES | 1 |
| Baumann, G; Garbe, E; Jochmann, N; Stangl, K; Stangl, V | 1 |
| Banasiak, W; Derkacz, A; Jankowska, E; Kaczmarek, A; Ponikowski, P; Porada, A; Rzeczuch, K; Szajn, G; Telichowski, A | 1 |
| Clase, CM; Cox, JL; Dipchand, CS; Keough-Ryan, TM; Kiberd, BA; Rose, CL; Thompson, KJ | 1 |
| Bax, JJ; Feringa, HH; Poldermans, D; Schouten, O | 1 |
| Roffi, M; Yadav, JS | 1 |
| Govindarajan, G; Kurukulasuriya, LR; Sowers, J | 1 |
| Ornato, JP | 1 |
| Berry, C; Bourassa, MG; Tardif, JC | 1 |
| Blinc, A; Poredos, P | 1 |
| Jamieson, MJ; Naghavi, M | 1 |
| Enlund, H; Hartikainen, SA; Hiitola, PK; Sulkava, RO | 1 |
| Gothe, H; Häussler, B; Hempel, E; Schiffhorst, G | 1 |
| Camargo, EG; Gross, JL; Lavinsky, J; Silveiro, SP; Weinert, LS | 1 |
| Ball, P; Curran, S; Granmyr, J; Wang, L | 1 |
| Alexander, KP; Armstrong, PW; Aylward, PE; Bhapker, MV; Califf, RM; Hochman, JS; Newby, LK; Pfisterer, M; Van de Werf, F; White, HD; Wong, CK | 1 |
| Kähönen, M; Kallio, J; Kööbi, T; Lehtimäki, T; Lehtinen, R; Michou, SM; Niemelä, K; Nieminen, T; Nikus, K; Turjanmaa, V; Viik, J | 1 |
| Farquhar, JW; Gardner, CD; Nicholus, JR; Rigby, AJ; Zehnder, JL | 1 |
| Matsuzaki, M | 1 |
| Fischer, T | 1 |
| de Belder, MA; Morley, R; Owens, WA; Roberts, AP; Thornley, AR; Turley, AJ | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Dobarro, D; Gómez-Rubín, MC; Moreno, R; Sánchez-Recalde, A | 1 |
| Chen, F; DU, X; Kang, JP; Liu, XH; Lü, Q; Lü, SZ; Ma, CS; Zhang, Q | 1 |
| Banasiak, W; Pociupany, R; Ponikowski, P; Wilkins, A | 1 |
| Kumar, V; Malik, S; Singh, S | 1 |
| Goldman, L; Moran, A | 1 |
| Bousser, MG | 1 |
| Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF | 1 |
| Dani, G; Katona, A; Kiss, Z; Márk, L | 1 |
| Hiatt, WR | 1 |
| Marshall, T | 1 |
| Forslund, L | 1 |
| Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S | 1 |
| Haruma, K; Hata, J; Imamura, H; Kamada, T; Kusunoki, H; Manabe, N; Sakakibara, T; Shiotani, A; Tarumi, K; Yamanaka, Y | 1 |
| Hartenthaler, B; Hofmann, R; Hönig, S; Kammler, J; Kerschner, K; Kypta, A; Lambert, T; Leisch, F; Steinwender, C | 1 |
| Angiolillo, DJ; Brugaletta, S; Campos, B; Cola, C; Martín Yuste, V; Sabaté, M | 1 |
| Abizaid, A; Bonan, R; Costa, JR; Costa, R; Feres, F; Mattos, LA; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF | 1 |
| Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ | 1 |
| Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H | 1 |
| Margolis, JR | 1 |
| Chandra, S; Lenihan, DJ; Tong, AT; Wei, W; Yusuf, SW | 1 |
| Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR | 1 |
| Kibbe, MR; Vavra, AK | 1 |
| Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC | 1 |
| De Berardis, G; Graziano, G; Nicolucci, A; Pellegrini, F; Sacco, M; Strippoli, GF; Tognoni, G | 1 |
| Armitage, J; Bowman, L; Haynes, R | 1 |
| Morgan, G | 1 |
| Bax, JJ; Flu, WJ; Hoeks, SE; Latour, C; Lenzen, MJ; Poldermans, D; Scholte op Reimer, WJ; Schouten, O; van Gestel, YR; van Kuijk, JP; van Urk, H | 1 |
| Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C | 1 |
| Balbi, M; Barsotti, A; Bezante, GP; Brunelli, C; Fedele, M | 1 |
| Kvan, E; Løchen, ML | 1 |
| Ando, M; Hida, K; Ishida, A; Kawasaki, T; Matsumoto, T; Matsuzaki, K; Miyata, T; Nishibe, T; Obitsu, Y; Ohta, T; Shigematsu, H; Shindo, S; Yasugi, T | 1 |
| Minar, E | 1 |
| Al-Dehneh, A; Alkhouri, Y; Bikkina, M; Hamdan, A; Virk, H | 1 |
| Kato, M; Nema, H | 1 |
| Kawai, T; Watanabe, M; Yamashina, A | 1 |
| Battler, A; Dvir, D | 1 |
| Anderson, FA; Eagle, KA; Fox, KA; Goldberg, RJ; Gore, JM; Gurfinkel, EP; Nguyen, HL; Quill, A; Reed, G; Spencer, FA | 1 |
| Alexander, GC; Conti, RM; Lindau, ST; Qato, DM; Schumm, LP | 1 |
| Björck, L; Lappas, G; Rosengren, A; Stenestrand, U; Wallentin, L | 1 |
| Herzog, E; Javed, F | 1 |
| Cho, BR; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Han, KR; Hur, SH; Lee, S; Lee, SH; Lee, SY; Lim, DS; Park, HS; Park, JS; Rha, SW; Song, YB; Yoon, J | 1 |
| Morimoto, T; Ogawa, H; Saito, Y; Soejima, H | 1 |
| Dissanayake, WP; Furberg, CD; Gunaratne, PS; Jayasingne, IK; Mendis, S; Soliman, EZ; Somasundaram, NP | 1 |
| Cunningham-Burley, S; Eborall, HC; Fowkes, FG; Price, JF; Stewart, MC | 1 |
| Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K | 1 |
| Bianchi, C; Cricelli, C; Filippi, A; Mazzaglia, G; Parazzini, F; Sessa, E | 1 |
| Butalia, S; Ghali, WA; Leung, AA; Rabi, DM | 1 |
| Holmes, D | 1 |
| Eikelboom, J; Hirsh, J; O'Donnell, M; Raju, N; Sobieraj-Teague, M | 1 |
| Blaha, MJ; Blumenthal, RS; Chang, HJ; Cho, IS; Choi, EK; Choi, SI; Chun, EJ; McEvoy, JW; Nasir, K; Rivera, JJ; Yoon, YE | 1 |
| Biondi-Zoccai, G; Landoni, G | 1 |
| de Maat, MP; Guchelaar, HJ; Jukema, JW; Simoons, ML; Trompet, S; Verschuren, JJ; Wessels, JA | 1 |
| Reidenberg, MM | 1 |
| Guggilla, RK; Lafeber, M; Patil, V; Singh, K; Spiering, W; Webster, R | 1 |
| Bonaventura, K; Kleber, FX; Sonntag, S | 1 |
| Antonoff, MB; D'Cunha, J | 1 |
| Morgan, GP | 1 |
| Lane, DA; Lip, GY; Tse, HF | 1 |
| Cleland, JG | 1 |
| Dean, L; Hazan, M; Vassilev, D | 1 |
| Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C | 1 |
| Doi, N; Jinnouchi, H; Kanauchi, M; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Sugiyama, S; Uemura, S; Waki, M | 1 |
| Akita, S; Akiyama, J; Fukuda, S; Hosaka, S; Kashima, T; Kimura, S; Mizoue, T; Ozawa, N | 1 |
| Chopra, V; Hayward, RA | 1 |
| Kemmner, W; Ma, C; Man, Y; Wang, Q | 1 |
| Manzano-Fernández, S; Marín, F; Tello-Montoliu, A | 1 |
| Asch, DA; Bradlow, ET; Werner, RM | 1 |
| Abbasi, N; Daher, IN; Daraban, N; Durand, JB; Lei, X; Yusuf, SW | 1 |
| Cariati, A; Piromalli, E | 1 |
| Bestwick, JP; Naderi, SH; Wald, DS | 1 |
| Chen, Y; Xu, LC; Zeng, S; Zhou, Q; Zhu, LL | 1 |
| Xue, ZY; Zhang, SJ | 1 |
| Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y | 1 |
| Cohn, JN; Garberich, RF; Graham, KJ; Henry, TD; Knickelbine, T; Miedema, MD | 1 |
| Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G | 1 |
| Andrews, JS; Chacko, BG; Hansen, KJ; Levy, PJ; Rana, H | 1 |
| Tsukada, YT | 1 |
| Badri, M; Saeed, W; Sardar, MR | 1 |
| Gao, RL; Han, YL; Jiang, TM; Jing, QM; Li, SM; Li, WM; Li, Y; Liu, HL; Qu, P; Xu, B; Yang, LX; Zhang, L; Zhang, QY | 1 |
| Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL | 1 |
| Bachorzewska-Gajewska, H; Dobrzycki, S; Kozuch, M; Malyszko, J; Musial, WJ; Tomaszuk-Kazberuk, A | 1 |
| Abakay, O; Akkoyun, CD; Bulut, I; Cetinkaya, E; Elitok, A; Ersin, G; Gibson, MC; Gul, S; Kaya, MG; Oflaz, H; Oncul, A; Oz, F; Yazici, M | 1 |
| Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y | 1 |
| Chang, FH; Chang, PY; Chang, SF; Chen, CH; Chen, YJ; Huang, WH; Lee, YT; Lu, J; Lu, SC; Yang, TC | 1 |
| Borzak, S; DeMets, D; Hennekens, CH; Hetzel, S; Schneider, R; Schneider, W; Schröder, H; Serebruany, V | 1 |
| Cushman, M; Glasser, SP; Hovater, MK; Howard, G; Howard, VJ; Lackland, DT | 1 |
| De Backer, G; De Backer, T; Matthys, F; Stichele, RV | 1 |
| Baloum, V; Boulom, V; Cambria, RP; Conrad, MF; Garg, A; Mukhopadhyay, S; Patel, VI | 1 |
| Cohn, S; Deller, R; Edwards, D; Fletcher, K; Giles, M; Hobbs, V; Lasserson, D; Mant, J; McGuire, G; McManus, R; Norrie, J; Sims, D; Weir, C; Whittle, F | 1 |
| Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y | 1 |
| Chehab, BM; Gupta, K | 1 |
| Absi, M; Bruce, JI; Ward, DT | 1 |
| Fleming, DW; Gillespie, CW; Mokdad, AA; Mokdad, AH; Murray, CJ; Roth, GA; Shen, DD; Stergachis, A | 1 |
| Volkov, I | 1 |
| Asciutto, R; Bosetti, C; Gallus, S; La Vecchia, C; Lugo, A; Parazzini, F | 1 |
| Laranjo, S; Oliveira, M; Rocha, I; Tavares, C | 1 |
| Abbott, A; Geroulakos, G; Mikhailidis, DP; Nicolaides, AN; Sillesen, H; Veith, FJ | 1 |
| Cambria, RP; Conrad, MF | 1 |
| Barry, AR; Koshman, SL; Norris, CM; Pearson, GJ; Ross, DB | 1 |
| Cambria, RP; Conrad, MF; LaMuraglia, GM; Michalczyk, MJ; Opalacz, A; Patel, VI | 1 |
| Ahmed, FR; Khan, MA; Manzoor, S; Nasiri, MI; Salam, FA; Shoaib, MH; Sultan, F; Yousuf, RI | 1 |
| Agmadova, ZM; Kallaeva, AN | 1 |
| Ambrosio, G; Clare, RM; Ferguson, TB; Fremes, S; Harrington, RA; Lira, A; Menasché, P; Mongero, L; Newman, MF; Nussmeier, N; Pearl, RG; Pieper, KS; Pitt, B; Reece, TL; Wechsler, AS; Weisel, RD; Yau, TM | 1 |
| Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN | 1 |
| Bhatt, DL; Cannon, CP; Deedwania, P; Fonarow, GC; Grau-Sepulveda, M; Hernandez, AF; Kumbhani, DJ; Laskey, WK; Peacock, WF; Peterson, ED; Schwamm, LH | 1 |
| Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R | 1 |
| Arnold, SV; Bhatt, DL; Bradley, SM; Ho, PM; Jones, PG; Maddox, TM; Parashar, S; Peterson, P; Shore, S; Spertus, J; Stolker, JM | 1 |
| Abiles, E; Bunce, A; Chan, W; Cowburn, S; Davis, J; DeVoe, J; Dudl, J; Gold, R; Hill, C; Hollombe, C; Howard, C; Jaworski, V; Mercer, M; Mital, M; Muench, J; Nelson, C; Nichols, G; Perrin, N; Puro, J; Shah, A; Turner, A | 1 |
| Devereaux, PJ; Duceppe, E; Mrkobrada, M; Thomas, S | 1 |
| Bonham, L; Donnelly, RF; Hughes, CM; Quinn, HL | 1 |
| Azevedo, A; Bennett, K; Dias, P; Laszczynska, O; Lopes-Conceição, L; Lunet, N; Pereira, M | 1 |
| Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F | 1 |
| Nansseu, JR; Noubiap, JJ | 1 |
| Julian, DG; Pocock, SJ; Rossello, X | 1 |
| Avezum, A; Chifamba, J; Chow, C; Dagenais, G; Diaz, R; Gafni, A; Gupta, R; Ismail, N; Kazmi, K; Kelishadi, R; Khatib, R; Kruger, A; Kumar, R; Lanas, F; Lear, SA; Lopez-Jaramillo, P; McKee, M; Mohan, V; Monsef, N; Mony, P; Puoane, T; Rahman, O; Rangarajan, S; Rosengren, A; Shannon, H; Szuba, A; Temizhan, A; Teo, K; Vijayakumar, K; Wei, L; Yusoff, K; Yusuf, S | 1 |
| Dong, X; Wang, X; Wei, L; Yin, Z; Zhang, L; Zhou, H | 1 |
| Bachmann, M; Clark, A; Fleetcroft, R; Myint, PK; Sarev, T; Stirling, S; Zaman, MJ | 1 |
| Bennett, K; Ensor, J; Grimes, RT; Henman, MC | 1 |
| Castellano, JM; Fuster, V; Tamargo, J | 1 |
| Cohen, DJ; Cutlip, DE; Hermiller, JB; Hsieh, WH; Kereiakes, DJ; Krucoff, MW; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Yeh, RW | 1 |
| Aneja, P; Horgan, AM; Knox, JJ; Le, LW; McKeever, E; McNamara, MG | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Einecke, D | 1 |
| Fort, JG; Goldstein, JL; Scheiman, JM; Whellan, DJ | 1 |
| Cook, NR; Dorresteijn, JA; Kaasenbrood, L; Ridker, PM; van der Graaf, Y; van Kruijsdijk, RC; Visseren, FL | 1 |
| Stiefelhagen, P | 1 |
| Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH | 1 |
| Batrićević, G; Bošković, A; Bulatović, N; Kalezić, M; Knežević, B; Musić, L; Nenezić, A; Vujović, J | 1 |
| Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW | 1 |
| Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI | 1 |
| Hilleman, DE; Packard, KA | 1 |
| Godley, RW; Hernandez-Vila, E | 1 |
| Ahmed, A; Ali, H; Howell, LE; Murtaza, A; Shaaban, A | 1 |
| Boersma, E; Diletti, R; Fam, JM; Felix, CM; IJsselmuiden, AJJ; Lansink, WJ; Onuma, Y; Regar, ES; Smits, PC; van Geuns, RJM; Vlachojannis, GJ; Zijlstra, F | 1 |
| Battistoni, A; Coluccia, R; De Caterina, R; Gallo, G; Volpe, M | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I | 1 |
| Barron, TI; Bennett, K; Brown, C; Cranfield, F; Murphy, L; Sharp, L; Smith, A; Visvanathan, K | 1 |
| Hamad, SR; Mohamed, HRH | 1 |
| Duval, S; Hirsch, AT; Kopecky, SL; Luepker, RV; Van't Hof, JR; Walts, A | 1 |
| Fernández-Urrusuno, R; Montero-Balosa, MC; Vilches-Arenas, A | 1 |
| Chalouhi, N; Hasan, DM; Jabbour, P; Nakagawa, D; Starke, RM; Torner, J; Zanaty, M | 1 |
| Cho, DK; Choi, S; Hong, BK; Hong, MK; Jang, Y; Jeon, DW; Kang, TS; Kang, WC; Kim, BK; Kim, BO; Kim, JS; Kim, S; Kim, YH; Kwon, HM; Lee, BK; Lee, OH; Min, PK; Shin, DH; Woo, SI; Yoon, YW | 1 |
| Ghandi, Y; Kamali, A; Sharifi, M | 1 |
| Caulfield, M; Fitzgerald, DJ; Ho, E; Howard, P; Hughes, AD; Johnson, T; McCarthy, NS; Munroe, PB; O'Brien, E; Rooney, C; Sever, P; Shields, DC; Stanton, AV; Surendran, P; Thom, S; Treumann, A; Vangjeli, C | 1 |
| Andrés Marín, N; Antigüedad-Muñoz, J; Arenaza Choperena, G; de la Riva, P; Fernández-Eulate, G; Martínez Zabaleta, M; Moreno Valladares, M; Muñoz Lopetegi, A | 1 |
| Abraham, P; Florczak, AS; Hamel, JF; Henni, S; Humeau-Heurtier, A; Rousseau, P; Signolet, I | 1 |
| Aleksic, N; Babic, S; Calija, B; Gajin, P; Ilijevski, N; Maravic-Stojkovic, V; Matic, P; Nenezic, D; Popov, P; Radak, D; Rancic, Z; Tanaskovic, S; Vasic, D; Vucurevic, G | 1 |
| Broström, A; Lin, CY; Nilsen, P; Pakpour, AH | 1 |
| Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E | 1 |
| Thilaganathan, B | 1 |
| Smulyan, H | 1 |
| Banach, M; Franczyk, B; Gluba-Brzózka, A; Jurkiewicz, Ł; Penson, P; Rysz, J | 1 |
| De Caterina, R; Minelli, S; Montinari, MR | 1 |
| Tousoulis, D | 1 |
| Barmanray, R; Hamblin, PS | 1 |
| Baniya, R; Khan, J; Madala, S; Saginala, K; Upadhaya, S | 1 |
| Duval, S; Eder, MM; Hirsch, AT; Kne, L; Krzyzanowski, B; Luepker, RV; Manson, SM; Oldenburg, N; Peterson, K | 1 |
| Buring, JE; Gaziano, JM; Khunti, K; Kunutsor, SK; Roncaglioni, MC; Seidu, S; Sesso, HD | 1 |
| Boehme, P; Kleinerüschkamp, AG; Thürmann, PA | 1 |
| Bachuwa, G; Barbarawi, M; Kheiri, B; Shapiro, MD | 1 |
| Al-Abdouh, A; Alkotob, ML; Bachuwa, G; Barbarawi, M; Barbarawi, O; Gakhal, I; Kheiri, B; Rashdan, L; Rizk, F; Zayed, Y | 1 |
| Bruggmann, C; Fesselet, R; Gex-Fabry, M; Iglesias, JF; Sadeghipour, F; Vogt, P; Voirol, P | 1 |
| Ajrouche, A; De Rycke, Y; Estellat, C; Tubach, F | 1 |
| Alison, L; Catriona, MD; Chris, F; Christine, M; David, T; Debbie, R; Ellie, L; Gerard, S; Hannah, B; Helen, T; Ian, C; Illary, S; Jo, D; Keith, H; Laura, C; Laurie, W; Liz, C; Martin, B; Peter, V; Rachael, F; Rhian, G; Robert, H | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
| Patel, A; Praveen, D; Salam, A; Tewari, A; Webster, R | 1 |
| Al-Sofiani, ME; Derenbecker, R; Kalyani, RR; Quartuccio, M | 1 |
| Alexander, JH; Aronson, R; Averkov, O; Budaj, A; Darius, H; Goodman, SG; Granger, CB; Guimaraes, PO; Kobalava, Z; Kong, DF; Lopes, RD; Mehran, R; Mehta, RH; Mirza, Z; Parkhomenko, A; Quadros, A; Thiele, H; Vora, AN; Windecker, S; Wojdyla, DM | 1 |
| Alexander, JH; Aronson, R; Aschermann, M; Brieger, D; Cura, F; Darius, H; de Waha-Thiele, S; Engstrøm, T; Fridrich, V; Goodman, SG; Granger, CB; Halvorsen, S; Heizer, G; Huber, K; Jones, WS; Jones-Burton, C; Kang, HJ; Leiva-Pons, JL; Lewis, BS; Lopes, RD; Malaga, G; Massaro, T; Mehran, R; Meneveau, N; Merkely, B; Milicic, D; Morais, J; Potpara, TS; Raev, D; Sabaté, M; Welsh, RC; Windecker, S; Xavier, D | 1 |
| Asgedom, SW; Atey, TM; Ayalew, E; Desta, DM; Hailu, A; Kasahun, GG; Nedi, T; Tsadik, AG | 1 |
| Akselrod, D; Bhave, A; Dewald, A; Michell, H; Morris, C; Nezami, N | 1 |
| Acierno, C; Adinolfi, LE; Bono, V; Caturano, A; Costagliola, C; de Sio, C; Galiero, R; Gelso, A; Marfella, R; Nevola, R; Pafundi, PC; Rinaldi, L; Salvatore, T; Sardu, C; Sasso, FC; Vetrano, E | 1 |
| Deoker, A; Lehker, A; Mukherjee, D | 1 |
| Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y | 1 |
| Liuzzo, G; Patrono, C | 1 |
| Huffman, MD; Patel, A | 1 |
| de Cássia Bergamaschi, C; Ferreira, TR; Lopes, LC; Motter, FR | 1 |
| Du, G; Du, L; Kong, L; Li, S; Liu, C; Wang, S; Zhang, S; Zhang, W | 1 |
| Bagheri, A; Khandan, M; Khazeei Tabari, MA; Khoshhal, H; Mahrooz, A; Mishan, MA; Moradi, M | 1 |
| Abidi, SM; Ahmed, H; Faizan, M; Jawed, F; Khan, AA; Lashkerwala, SS; Moin, A; Murtaza, N; Shah, SMI; Shahid, MH; Siddiqui, SA; Tariq, R; Ullah, I; Yasmin, F; Yousaf, Z | 1 |
| Abdallah, NA; El-Awady, MI; El-Brashy, AM; Ibrahim, FA | 1 |
| Albert-Stone, E; Davis, MB; Spehar, SM | 1 |
| Tran, RJC | 1 |
61 review(s) available for aspirin and cardiovascular agents
| Article | Year |
|---|---|
The secondary prevention of myocardial infarction by drug treatment; excluding lipid lowering agents.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Humans; Hypertension; Myocardial Infarction; Recurrence | 1992 |
Atherothrombotic insights into secondary prevention after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Combined Modality Therapy; Coronary Artery Disease; Coronary Circulation; Humans; Hyperlipidemias; Hypolipidemic Agents; Myocardial Infarction; Thrombolytic Therapy; Warfarin | 1993 |
[Myocardial infarct: acute intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Combined Modality Therapy; Emergencies; Female; Humans; Male; Myocardial Infarction; Survival Rate; Thrombolytic Therapy | 1993 |
Therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Female; Humans; Male; Myocardial Infarction; Thrombolytic Therapy | 1996 |
Management of postmyocardial infarction in the elderly patient.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Estrogens; Female; Humans; Hyperlipidemias; Hypertension; Male; Myocardial Infarction; Risk Factors; Smoking | 1996 |
[Drug therapy for prognostic improvement after acute myocardial infarct].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Humans; Myocardial Infarction; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 1999 |
[Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Cost-Benefit Analysis; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention | 2001 |
Cardiovascular risk reduction in renal transplantation. Strategies for success.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Heart Function Tests; Humans; Hyperlipidemias; Hypertension; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Life Expectancy; Pancreas Transplantation; Postoperative Complications; Prevalence; Renal Dialysis; Risk Reduction Behavior; Smoking Cessation; Treatment Outcome | 2002 |
[Management of atherosclerotic renal artery stenoses].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Cardiovascular Agents; Combined Modality Therapy; Creatinine; Diagnostic Imaging; Drug Therapy, Combination; Heart Failure; Humans; Hypertension, Renovascular; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Pulmonary Edema; Radionuclide Imaging; Renal Artery; Renal Artery Obstruction; Risk Factors; Stroke | 2002 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Calcium Channels; Cardiovascular Agents; Clinical Trials as Topic; Coronary Circulation; Death, Sudden, Cardiac; Diet; Exercise; Heart Failure; Humans; Hypolipidemic Agents; Life Style; Myocardial Infarction; Myocardial Revascularization; Nitric Oxide Donors; Risk Factors; Secondary Prevention; Smoking Cessation; Vasodilator Agents | 2002 |
NEWER DRUGS IN THE TREATMENT OF HEADACHE.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Cardiovascular Agents; Carisoprodol; Chlordiazepoxide; Classification; Dextropropoxyphene; Ergot Alkaloids; Ergotamine; Headache; Humans; Meprobamate; Methocarbamol; Methysergide; Muscle Relaxants, Central; Salicylamides; Serotonin | 1964 |
[Risk management of coronary artery disease--pharmacological therapy].
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Drug Therapy, Combination; Homocysteine; Humans; Nitroglycerin; Risk Factors | 2004 |
[Stroke and other thromboembolic complications of atrial fibrillation. Part VI. Choice of optimal approach and drugs for prevention of stroke].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Electric Countershock; Fibrinolytic Agents; Humans; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Warfarin | 2005 |
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Digitalis Glycosides; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Sex Factors; Ticlopidine; Women's Health | 2005 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular Agents; Carotid Stenosis; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Dyslipidemias; Humans; Hypertension; Insulin Resistance; Ischemic Attack, Transient; Leptin; Life Style; Lipoproteins; Obesity; Plasminogen Activator Inhibitor 1; Risk Factors; Smoking; Stroke | 2006 |
Accelerating time to reperfusion in acute myocardial infarction: prehospital and emergency department strategies, systems of care, and pharmacologic interventions.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelets; Cardiovascular Agents; Clopidogrel; Community Health Services; Critical Pathways; Emergency Medical Services; Emergency Service, Hospital; Fibrinolytic Agents; Health Services Accessibility; Heparin; Humans; Myocardial Infarction; Patient Care Team; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Program Development; Ticlopidine; Time Factors; Treatment Outcome; Triage; United States | 2006 |
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Health Behavior; Humans; Hyperglycemia; Hypertension; Insulin Resistance; Life Style; Metabolic Syndrome; Treatment Refusal | 2007 |
Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperhomocysteinemia; Hypertension; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Risk Factors; Thrombosis | 2007 |
Multi-constituent cardiovascular pills (MCCP)--challenges and promises of population-based prophylactic drug therapy for prevention of heart attack.
Topics: Antihypertensive Agents; Aspirin; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Drug Therapy; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Primary Prevention; Vitamin B Complex | 2007 |
[Drug-induced depression].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Cardiovascular Agents; Depression; Glucocorticoids; Histamine H1 Antagonists; Humans; Interferons; Reserpine; Time Factors | 2007 |
[New possibilities in the pharmacologic prevention of age-related macular degeneration].
Topics: Adrenergic Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular Degeneration; Oxidative Stress; Platelet Aggregation Inhibitors; Primary Prevention; Risk Factors; Trimetazidine; Vasodilation; Vasodilator Agents | 2008 |
Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008.
Topics: Aspirin; Awards and Prizes; Biomedical Research; CADASIL; Cardiovascular Agents; Cardiovascular Diseases; Cerebral Infarction; Craniotomy; Evidence-Based Medicine; Female; Foramen Ovale, Patent; Humans; Male; Medical Records; Migraine Disorders; Myocardial Infarction; Neurology; Randomized Controlled Trials as Topic; Receptor, Notch3; Receptors, Notch; Sex Factors; Treatment Outcome | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
[A change of attitude in lipidology, achievement of target levels. What comes next?].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Attitude of Health Personnel; Cardiovascular Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Physicians; Program Evaluation | 2008 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Sirolimus; Ticlopidine; Treatment Outcome | 2009 |
Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
Topics: Aspirin; Blood Coagulation; Blood Glucose; Blood Platelets; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Metabolic Syndrome; Treatment Outcome | 2009 |
Women and peripheral arterial disease.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Comorbidity; Estrogen Replacement Therapy; Exercise; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Peripheral Vascular Diseases; Postmenopause; Prevalence; Risk Factors; Sex Factors; Smoking; Women's Health | 2009 |
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.
Topics: Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Female; Humans; Male; Primary Prevention; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors | 2009 |
[Sex differences and cardiovascular drugs].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Female; Fibrinolytic Agents; Humans; Male; Sex Characteristics; Sex Factors; Treatment Outcome | 2010 |
Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug-Eluting Stents; Electrocardiography; Humans; Male; Middle Aged; Neurosurgical Procedures; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Conventional and novel drug therapeutics to relief myocardial ischemia.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Cardiovascular System; Coronary Artery Disease; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Nicorandil; Nitrates; Piperazines; Ranolazine | 2010 |
Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Evidence-Based Medicine; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Incidence; Male; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Agents; Cause of Death; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Randomized Controlled Trials as Topic; Risk Assessment; Stroke | 2011 |
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Topics: Adrenergic alpha-Antagonists; Anticoagulants; Apolipoproteins E; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Resistance; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinesins; Muscular Diseases; Peptidyl-Dipeptidase A; Pharmacogenetics; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Renin-Angiotensin System; Risk Factors | 2012 |
The cardiovascular polypill in high-risk patients.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; History, 20th Century; History, 21st Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polypharmacy; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Secondary Prevention; Tablets; Treatment Outcome | 2012 |
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Delivery Systems; Drug Therapy, Combination; Equipment Design; Evidence-Based Medicine; Humans; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Atrial fibrillation.
Topics: Administration, Oral; Algorithms; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiovascular Agents; Catheter Ablation; Decision Trees; Electric Countershock; Humans; Patient-Centered Care; Risk Factors; Stroke; Warfarin | 2012 |
Cardiovascular medications in angiogenesis--how to avoid the sting in the tail.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neovascularization, Pathologic; Neovascularization, Physiologic | 2012 |
Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.
Topics: Administration, Oral; Animals; Aspirin; Atherosclerosis; Cardiovascular Agents; Cholecystolithiasis; Cholesterol; Dyslipidemias; Gallbladder; Gallstones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Cardiovascular Diseases; Drug Administration Schedule; Drug Costs; Drug Prescriptions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Secondary Prevention; Self Administration; Sodium Chloride Symporter Inhibitors; Time Factors | 2012 |
Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Prosthesis Implantation; Stents | 2012 |
Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
Topics: Aspirin; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus; Evidence-Based Medicine; Hemorrhage; Humans; Patient Selection; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
Contemporary diagnosis of carotid fibromuscular dysplasia: role of power Doppler and a review of other diagnostic modalities.
Topics: Aspirin; Cardiovascular Agents; Carotid Artery Diseases; Female; Fibromuscular Dysplasia; Humans; Magnetic Resonance Angiography; Middle Aged; Predictive Value of Tests; Tomography, X-Ray Computed; Ultrasonography, Doppler; Ultrasonography, Doppler, Color | 2013 |
Role of aspirin for prevention and treatment of perioperative cardiovascular events.
Topics: Animals; Aspirin; Cardiovascular Agents; Drug Administration Schedule; Hemorrhage; Humans; Myocardial Infarction; Perioperative Period; Risk Assessment; Risk Factors; Surgical Procedures, Operative; Time Factors; Treatment Outcome | 2015 |
Trends in pharmacological therapy following an acute coronary syndrome in Portugal: a systematic review.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clopidogrel; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Secondary Prevention; Ticlopidine | 2016 |
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
Topics: Animals; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Ticlopidine | 2015 |
Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomedical Research; Cardiovascular Agents; Cardiovascular Diseases; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Care; Randomized Controlled Trials as Topic | 2015 |
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2015 |
Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Medication Adherence; Recurrence; Risk Factors; Secondary Prevention; Treatment Outcome | 2016 |
Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Topics: Aspirin; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Hemorrhage; Humans; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Treatment Outcome | 2017 |
The first 3500 years of aspirin history from its roots - A concise summary.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Aspirin; Cardiovascular Agents; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Plant Bark; Plant Leaves; Platelet Aggregation Inhibitors; Salix | 2019 |
Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Prognosis; Protective Factors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2019 |
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Primary Prevention; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Young Adult | 2019 |
Aspirin for Primary Prevention of Cardiovascular Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Agents; Cause of Death; Evidence-Based Medicine; Hemorrhage; Humans; Primary Prevention; Protective Factors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Hemorrhage; Humans; Incidence; Primary Prevention; Protective Factors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2019 |
Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Humans; Primary Prevention; Risk Assessment | 2019 |
Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Agents; Humans; Platelet Aggregation Inhibitors; Proprotein Convertase 9 | 2020 |
Differences in the prevention and control of cardiovascular and cerebrovascular diseases.
Topics: Animals; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Primary Prevention; Prognosis; Protective Factors; Risk Assessment; Risk Factors | 2021 |
Noncoding RNA Roles in Pharmacogenomic Responses to Aspirin: New Molecular Mechanisms for an Old Drug.
Topics: Animals; Aspirin; Cardiovascular Agents; Gene Expression; Humans; Pharmacogenetics; Prescription Drugs; RNA, Untranslated | 2021 |
The Era of Polypills in the Management of Cardiovascular Diseases: Are We There Yet?
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Quality of Life | 2023 |
Cardiac medications in obstetric patients.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Female; Hematologic Agents; Humans; Hypertension; Labetalol; Platelet Aggregation Inhibitors; Pre-Eclampsia; Pregnancy | 2023 |
41 trial(s) available for aspirin and cardiovascular agents
| Article | Year |
|---|---|
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.
Topics: Adult; Aged; Aspirin; Calcium Channel Blockers; Captopril; Cardiomegaly; Cardiovascular Agents; Diltiazem; Drug Utilization; Female; Humans; Male; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; United States | 1992 |
[Drug prescription in myocardial postinfarction: results of the EPPI (étude de prescription postinfarctus). A French cooperative study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Drug Prescriptions; France; Health Surveys; Humans; Middle Aged; Myocardial Infarction; Surveys and Questionnaires; Vasodilator Agents | 1990 |
The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue.
Topics: Adult; Antigens; Aspirin; Cardiovascular Agents; Epoprostenol; Fibrinolysis; Glycoproteins; Hemostasis; Humans; Iloprost; Male; Plasminogen Activators; Plasminogen Inactivators; Tissue Plasminogen Activator | 1989 |
Inhibition of thrombocyte aggregation by oral motapizone and other drugs.
Topics: Adult; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Female; Fibrinolytic Agents; Humans; Male; Platelet Aggregation; Pyridazines | 1986 |
[Diltiazem versus intravenous nitroglycerin in the treatment of unstable angina pectoris. A randomized study].
Topics: Aged; Analysis of Variance; Angina, Unstable; Anticoagulants; Aspirin; Blood Pressure; Cardiovascular Agents; Diltiazem; Female; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Nitroglycerin; Platelet Aggregation Inhibitors; Prospective Studies; Vasodilator Agents | 1995 |
[The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty].
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Cardiovascular Agents; Dipyridamole; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pilot Projects; Platelet Activation; Recurrence; Treatment Outcome | 1996 |
Differences in discharge medication after acute myocardial infarction in patients with HMO and fee-for-service medical insurance.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Confidence Intervals; Drug Utilization; Fee-for-Service Plans; Female; Health Maintenance Organizations; Humans; Male; Massachusetts; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Discharge; Population Surveillance; Prospective Studies | 1999 |
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Cilostazol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Tetrazoles; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Protecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgery.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Dobutamine; Echocardiography; Endpoint Determination; Female; Heart Diseases; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intraoperative Complications; Male; Middle Aged; Vascular Surgical Procedures; Ventricular Dysfunction, Left | 2006 |
The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Enalapril; Female; Humans; Male; Middle Aged; Proteinuria | 2007 |
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cardiovascular Agents; Evidence-Based Medicine; Female; Humans; Male; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors | 2007 |
Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cohort Studies; Coronary Disease; Exercise Test; Female; Finland; Hospitals, University; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Practice Patterns, Physicians'; Risk Factors; Sex Factors; Smoking | 2007 |
Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Agents; Double-Blind Method; Drug Therapy, Combination; Female; Ginkgo biloba; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Plant Extracts; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests | 2007 |
Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Outpatients; Platelet Aggregation Inhibitors; Poland | 2008 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome | 2009 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymers; Product Surveillance, Postmarketing; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Sirolimus; Ticlopidine | 2009 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol; Diuretics; Drug Combinations; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Primary Prevention; Risk Assessment; Risk Factors; Simvastatin; Sri Lanka; Surveys and Questionnaires; Time Factors; Treatment Outcome; World Health Organization | 2011 |
Accrual and drop out in a primary prevention randomised controlled trial: qualitative study.
Topics: Aged; Aspirin; Asymptomatic Diseases; Atherosclerosis; Cardiovascular Agents; Female; Focus Groups; Health Behavior; Health Knowledge, Attitudes, Practice; Humans; Interviews as Topic; Male; Middle Aged; Motivation; Patient Dropouts; Patient Education as Topic; Patient Selection; Primary Prevention; Qualitative Research; Risk Assessment; United Kingdom | 2011 |
Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Bandages, Hydrocolloid; Cardiovascular Agents; Chi-Square Distribution; Chronic Disease; Combined Modality Therapy; Compression Bandages; Debridement; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Spain; Time Factors; Treatment Outcome; Varicose Ulcer; Venous Insufficiency; Wound Healing | 2012 |
Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
Topics: Aged; Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypertension; Incidence; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Primary Prevention; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia.
Topics: Aged; Aspirin; Blood Flow Velocity; Cardiovascular Agents; Cerebrovascular Disorders; Cognition Disorders; Drug Administration Schedule; Drug Therapy, Combination; Female; Ginkgo biloba; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Plant Extracts; Platelet Aggregation Inhibitors; Psychological Tests; Treatment Outcome | 2012 |
Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Cardiovascular Agents; Chi-Square Distribution; Electrocardiography; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pneumonia; Primary Prevention; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Troponin T; Turkey | 2013 |
Aspirin increases nitric oxide formation in chronic stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Aspirin; Biomarkers; Cardiovascular Agents; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Down-Regulation; Female; Heme Oxygenase-1; Humans; Male; Middle Aged; Nitric Oxide; Platelet Aggregation Inhibitors; Tablets, Enteric-Coated; Up-Regulation | 2013 |
RApid Primary care Initiation of Drug treatment for Transient Ischaemic Attack (RAPID-TIA): study protocol for a pilot randomised controlled trial.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Clinical Protocols; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination; Emergency Service, Hospital; England; Feasibility Studies; General Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pilot Projects; Primary Health Care; Referral and Consultation; Research Design; Secondary Prevention; Simvastatin; Time Factors; Treatment Outcome | 2013 |
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug Therapy, Combination; Endothelium, Vascular; Female; Health Behavior; Hemodynamics; Humans; Hypercholesterolemia; Life Style; Lipids; Male; Middle Aged; Platelet Aggregation Inhibitors; Probucol; Prospective Studies; Stroke, Lacunar; Tetrazoles; Vasodilation | 2014 |
Predictors of contemporary coronary artery bypass grafting outcomes.
Topics: Age Factors; Aminoimidazole Carboxamide; Aspirin; Cardiopulmonary Bypass; Cardiovascular Agents; Chi-Square Distribution; Coronary Artery Bypass; Double-Blind Method; Heart Failure; Humans; Logistic Models; Multivariate Analysis; Odds Ratio; Patient Selection; Peripheral Arterial Disease; Protective Factors; Ribonucleosides; Risk Assessment; Risk Factors; Stroke; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan | 2015 |
Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: a cluster-randomized trial.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Community Health Centers; Diabetes Complications; Diabetes Mellitus; Female; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Quality Improvement; Quality Indicators, Health Care; Safety-net Providers; Young Adult | 2015 |
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Pyridines; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Topics: Adolescent; Adult; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Drug Combinations; Drug Compounding; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Logistic Models; Male; Middle Aged; Odds Ratio; Omeprazole; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Secondary Prevention; Stomach Ulcer; Tablets, Enteric-Coated; Time Factors; Treatment Outcome; Young Adult | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Intention to Treat Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Republic of Korea; Sirolimus; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Effect of Sustained Use of Aspirin until the Time of Surgery on Outcomes following Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
Topics: Aged; Aspirin; Blood Loss, Surgical; Cardiovascular Agents; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Erythrocyte Transfusion; Female; Hospital Mortality; Humans; Iran; Male; Middle Aged; Operative Time; Postoperative Hemorrhage; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Vasodilator response to galvanic current stimulation of the skin accurately detects acetylsalicylic acid intake: A study in 400 vascular patients.
Topics: Aged; Aspirin; Body Mass Index; Cardiovascular Agents; Drug Monitoring; Female; Galvanic Skin Response; Humans; Male; Medication Adherence; Middle Aged; Polypharmacy; Predictive Value of Tests; Skin; Transcutaneous Electric Nerve Stimulation; Vascular Diseases; Vasodilation | 2018 |
Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Male; Middle Aged; Primary Prevention; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Spain; Time Factors; Treatment Outcome | 2018 |
Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program.
Topics: Aged; Aspirin; Cardiovascular Agents; Community Health Services; Cross-Over Studies; Female; Geographic Information Systems; Humans; Male; Middle Aged; Minnesota; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Primary Prevention; Randomized Controlled Trials as Topic; Socioeconomic Factors; Software; Stroke | 2019 |
Aspirin versus placebo for the treatment of venous leg ulcers-a phase II, pilot, randomised trial (AVURT).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Compression Bandages; Double-Blind Method; Female; Humans; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome; United Kingdom; Varicose Ulcer; Wound Healing | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Combined Modality Therapy; Disease Management; Drug Therapy, Combination; Elective Surgical Procedures; Female; Fibrinolytic Agents; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Treatment Outcome; Vitamin K | 2019 |
Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial.
Topics: Aged; Angina, Stable; Aspirin; Cardiovascular Agents; Creatinine; Depsides; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Salvia miltiorrhiza; Thrombelastography; Treatment Outcome | 2021 |
181 other study(ies) available for aspirin and cardiovascular agents
| Article | Year |
|---|---|
Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Echocardiography; Exercise Test; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Nitrates; Patient Discharge | 1992 |
Platelet activity and stroke severity.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Calcium; Cardiovascular Agents; Collagen; Disease Susceptibility; Drug Interactions; Female; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Ibuprofen; Male; Middle Aged; Platelet Activation; Severity of Illness Index; Thrombin | 1992 |
Carotid endarterectomy in patients with heparin-induced platelet activation: comparative efficacy of aspirin and iloprost (ZK36374).
Topics: Aged; Aspirin; beta-Thromboglobulin; Cardiovascular Agents; Carotid Arteries; Drug Evaluation; Endarterectomy; Epoprostenol; Fibrinopeptide A; Heparin; Humans; Iloprost; Male; Platelet Activating Factor; Platelet Aggregation; Platelet Count; Platelet Factor 4; Preoperative Care; Thrombosis | 1987 |
Role of eicosanoids in the kappa-carrageenin rat tail thrombosis.
Topics: Aminopyrine; Animals; Aspirin; Benzydamine; Cardiovascular Agents; Carrageenan; Diclofenac; Epoprostenol; Female; Iloprost; Imidazoles; Phenylbutazone; Rats; Rats, Inbred Strains; Thrombosis; Thromboxanes; Trapidil | 1988 |
Surgery and long-term medication.
Topics: Antidepressive Agents, Tricyclic; Aspirin; Bronchodilator Agents; Cardiovascular Agents; Contraceptives, Oral; Drug Therapy; Hormones; Humans; Surgical Procedures, Operative | 1984 |
Failure of aspirin and diltiazem to prevent the formation of acute coronary thrombi in dogs.
Topics: Animals; Aspirin; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Coronary Thrombosis; Diltiazem; Dogs; Female; Heart Rate; Male; Platelet Aggregation Inhibitors | 1995 |
[Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Benzothiadiazines; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Drug Costs; Humans; Sodium Chloride Symporter Inhibitors | 1995 |
Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteries.
Topics: Animals; Arteries; Aspirin; Blood Platelets; Cardiovascular Agents; Constriction, Pathologic; Cyclic GMP; Drug Evaluation, Preclinical; Drug Synergism; Nitric Oxide; Nitroglycerin; Organometallic Compounds; Rabbits; Random Allocation; Superoxide Dismutase; Thrombosis; Time Factors | 1995 |
Adverse drug reactions resulting in hospital admission.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Agents; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Hemorrhage; Humans; Length of Stay; Male; Medigoxin; Middle Aged; Patient Admission; Prospective Studies | 1994 |
Description of time- and frequency- domain-based measures of heart rate variability in individuals taking antiarrhythmics, beta blockers, calcium channel blockers, and/or antihypertensive drugs after sudden cardiac arrest.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Cardiac Glycosides; Cardiovascular Agents; Electrocardiography, Ambulatory; Female; Heart Arrest; Heart Rate; Humans; Male; Middle Aged; Nitrates | 1993 |
[Drug treatment following an infarction].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Cardiovascular Agents; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 1994 |
[Drug therapy as secondary prevention following myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Cardiovascular Agents; Humans; Myocardial Infarction; Recurrence | 1996 |
[What can we learn about mega-trials of drugs?].
Topics: Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Drug Therapy; Humans; Magnesium; Myocardial Infarction | 1995 |
Combined neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia.
Topics: Animals; Aspirin; Cardiovascular Agents; Cerebral Infarction; Cerebrovascular Disorders; Drug Therapy, Combination; Hemodilution; Hemoglobins; Male; Neuroprotective Agents; Piperidines; Rats; Rats, Inbred Strains; Reperfusion; Thiazoles | 1996 |
Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Australia; Calcium Channel Blockers; Cardiovascular Agents; Diabetes Mellitus; Diabetic Angiopathies; Drug Prescriptions; Drug Utilization; Evidence-Based Medicine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Registries; Streptokinase; Treatment Outcome | 1998 |
Is prophylactic treatment after myocardial infarction evidence-based?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Evidence-Based Medicine; Family Practice; Female; Humans; Male; Myocardial Infarction; Nitroglycerin; Platelet Aggregation Inhibitors; Prospective Studies; Spain; Vasodilator Agents | 1998 |
The management of stable angina.
Topics: Angina Pectoris; Angioplasty, Balloon; Aspirin; Cardiovascular Agents; Coronary Artery Bypass; Evidence-Based Medicine; Hospital Mortality; Hospitals, Public; Humans; Management Audit; Myocardial Infarction; State Medicine; United Kingdom | 1997 |
The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly.
Topics: Aged; Aspirin; Cardiovascular Agents; Digoxin; Humans; Hydrochlorothiazide; Patient Compliance; Propranolol; Reproducibility of Results | 1999 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E | 1999 |
Reflex cardiovascular response to brief abdominal visceral ischemia is mediated in part by prostaglandins.
Topics: Abdomen; Animals; Aspirin; Blood Pressure; Cardiovascular Agents; Cardiovascular System; Cats; Cyclooxygenase Inhibitors; Female; Indomethacin; Ischemia; Male; Prostaglandins; Reflex; Viscera | 1999 |
The Canadian Study of Cardiac Transplantation. Atherosclerosis. Investigators of the CASCADE Study.
Topics: Adult; Antihypertensive Agents; Arteriosclerosis; Aspirin; Cardiovascular Agents; Cyclosporine; Cytomegalovirus Infections; Diltiazem; Female; Follow-Up Studies; Heart Transplantation; Humans; Male; Middle Aged; Myocardial Ischemia; Postoperative Care; Postoperative Complications | 1999 |
Effect of angiopeptin and aspirin on accelerated graft atherosclerosis in transplanted mouse heart.
Topics: Animals; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Vessels; Heart; Heart Transplantation; Immunohistochemistry; Mice; Mice, Inbred Strains; Myocardium; Oligopeptides; Peptides, Cyclic; Somatostatin; Transplantation, Homologous; Tropomyosin | 1999 |
[Check list for the use of thrombolytics and other drugs in acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Agents; Drug Administration Schedule; Fibrinolytic Agents; Hospital Mortality; Humans; Middle Aged; Myocardial Infarction; Norway; Patient Admission; Prospective Studies; Registries; Retrospective Studies; Thrombolytic Therapy | 2000 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vasospasm; Diltiazem; Doxazosin; Drug Resistance; Drug Therapy, Combination; Ergonovine; Humans; Isosorbide Dinitrate; Male; Myocardial Infarction; Nicorandil; Nitrates; Pyridines; Stents; Ticlopidine; Ventricular Fibrillation | 2000 |
Studies on the effect of diadenlyated nucleotides on calcium mobilization and prostacyclin synthesis in bovine aortic endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Aspirin; Calcium; Cardiovascular Agents; Cattle; Cells, Cultured; Endothelium, Vascular; Epoprostenol; Fluorescent Dyes; Indomethacin; Nitric Oxide; Spectrometry, Fluorescence; Time Factors; Vasodilator Agents; Xanthenes | 2001 |
Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Therapy; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Outpatient Clinics, Hospital; Patient Compliance; Pharmacists; Platelet Aggregation Inhibitors; Retrospective Studies | 2002 |
[Increased thrombocyte activation in dilated cardiomyopathy: a risk factor for development of ventricular thrombosis despite anticoagulant therapy?].
Topics: Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Cardiovascular Agents; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Phenprocoumon; Platelet Activation; Risk Factors; Thrombosis; Treatment Failure; Ultrasonography | 2002 |
Experimental study of biological activity of angiogen in experimental cardiovascular and hemostasis pathology.
Topics: Animals; Aspirin; Blood Coagulation; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol; Drug Combinations; Hemostasis; Lipids; Male; Platelet Aggregation Inhibitors; Rats; Succinic Acid | 2002 |
Pravastatin and Aspirin.
Topics: Advisory Committees; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Packaging; Drug Therapy, Combination; Humans; Hypertension; Pravastatin | 2002 |
Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitric Oxide; Nitroprusside; Perhexiline; Platelet Aggregation; Platelet Aggregation Inhibitors; Severity of Illness Index; Statistics as Topic; Stroke Volume; Ventricular Function, Left | 2002 |
Cardiac arrest related to coronary spasm in patients with variant angina: a three-case study.
Topics: Amiodarone; Angina Pectoris, Variant; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; Diltiazem; Electrocardiography; Female; Follow-Up Studies; Heart Arrest; Heart Block; Humans; Male; Middle Aged; Nitrates; Nitroglycerin; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Spasm; Time Factors; Vasodilator Agents; Ventricular Fibrillation | 2002 |
Cardiovascular medications taken by patients aged >or=70 years hospitalized for acute coronary syndromes before hospitalization and at hospital discharge.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; Coronary Disease; Drug Utilization; Female; Hospitalization; Humans; Male; Myocardial Revascularization; Patient Discharge; Probability; Prognosis; Prospective Studies; Severity of Illness Index; Survival Rate | 2002 |
Implementing guidelines in primary care: can population impact measures help?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Fibrinolytic Agents; Health Status; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Primary Health Care; Risk Reduction Behavior; United Kingdom; Value of Life | 2003 |
The underutilization of cardiac medications of proven benefit, 1990 to 2002.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Coronary Artery Disease; Drug Therapy; Drug Utilization; Health Care Surveys; Heart Failure; Hematologic Agents; Humans; Longitudinal Studies; Office Visits; United States; Warfarin | 2003 |
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Cardiac Glycosides; Cardiac Output, Low; Cardiovascular Agents; Europe; Female; Fibrinolytic Agents; Health Surveys; Hospitalization; Humans; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Quality of Health Care; Spironolactone | 2003 |
Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Cardiovascular Agents; Drug Therapy; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction | 2002 |
Under-prescribing of cardiovascular therapies for diabetes in primary care.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Nitrates; Pharmacoepidemiology; Primary Health Care | 2003 |
Heart failure as a cause for hospitalization in chronic dialysis patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cohort Studies; Comorbidity; Drug Utilization; Female; Heart Failure; Hospitalization; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Peritoneal Dialysis; Recurrence; Renal Dialysis; Retrospective Studies; Risk Factors; Survival Analysis | 2003 |
Medical therapy in patients undergoing percutaneous coronary intervention: results from the ROSETTA registry.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Disease; Drug Therapy, Combination; Drug Utilization; Exercise Test; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Nitrates; Platelet Aggregation Inhibitors; Prospective Studies; Registries | 2003 |
[Migraine; current concept and therapy of migrainoid neurodystonia].
Topics: Aspirin; Caffeine; Cardiovascular Agents; Ergot Alkaloids; Migraine Disorders | 1953 |
Evaluation of the treatment of influenza with bioflavonoids and antibiotics.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Ascorbic Acid; Aspirin; Cardiovascular Agents; Dermatologic Agents; Flavonoids; Humans; Influenza, Human; Protein Synthesis Inhibitors; Tetracycline; Vitamins | 1958 |
[Use of carisoprodol and a combination of it with acetylsalicylic acid and metamyzol in rheumatology].
Topics: Aminopyrine; Aspirin; Cardiovascular Agents; Carisoprodol; Humans; Muscle Relaxants, Central; Rheumatic Diseases; Rheumatology | 1960 |
[On the analgesic strength of pyramidon, butazolidin and carisoprodol in comparison with that of aspirin].
Topics: Aminopyrine; Analgesics; Aspirin; Cardiovascular Agents; Carisoprodol; Muscle Relaxants, Central; Phenylbutazone | 1960 |
ADMINISTRATION OF DELENAR IN THE PRACTICE OF PODIATRY.
Topics: Aspirin; Cardiovascular Agents; Dexamethasone; Humans; Muscle Relaxants, Central; Podiatry | 1964 |
DRUGS FOR HEADACHE OF MIGRAINOUS, VASCULAR OR MUSCULAR ORIGIN.
Topics: Aspirin; Caffeine; Cardiovascular Agents; Ergot Alkaloids; Ergotamine; Headache; Humans; Meprobamate; Methysergide; Migraine Disorders; Oxytocics; Pharmacology; Phenacetin; Phenobarbital; Scopolamine; Toxicology | 1964 |
[CLINICAL TRIALS IN RHEUMATOLOGY OF MI315 BY THE "DOUBLE-BLIND" METHOD. STATISTICAL INTERPRETATION OF THE RESULTS].
Topics: Aspirin; Barbiturates; Biomedical Research; Cardiovascular Agents; Double-Blind Method; Drug Therapy; Gelatin; Joint Diseases; Lactose; Muscle Relaxants, Central; Placebos; Rheumatology; Starch; Talc | 1965 |
On the effects of SKF 525-A, caronamide, probenecid, salicylate and aspirin on the bioacetylation of sulfanilamide and choline.
Topics: Aspirin; Cardiovascular Agents; Choline; Muscle Relaxants, Central; Probenecid; Salicylates; Sulfanilamide; Sulfanilamides | 1959 |
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cohort Studies; Creatinine; Female; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prevalence; Prognosis; Proportional Hazards Models; Prospective Studies; Stroke Volume; Survival Analysis | 2004 |
Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Retinal Hemorrhage; Retrospective Studies; Vitreous Hemorrhage | 2004 |
[Pharmacological aspects of secondary prevention post-MI].
Topics: Aftercare; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Coronary Artery Disease; Fatty Acids, Omega-3; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Survival Rate; Treatment Outcome | 2004 |
The dream of a do-it-all "polypill". The reality: patients will probably keep taking separate heart drugs.
Topics: Age Factors; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Drug Combinations; Folic Acid; Humans; Middle Aged; Tablets | 2003 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Agents; China; Coronary Disease; Developing Countries; Diabetes Mellitus; Diet; Drug Utilization; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Models, Cardiovascular; Mortality; Obesity; Risk Factors; Smoking | 2004 |
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Cardiovascular Agents; Cohort Studies; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Paris; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Syndrome; Thrombosis; Treatment Outcome; Withholding Treatment | 2004 |
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cause of Death; Cohort Studies; Comorbidity; Coronary Artery Disease; Creatinine; Drug Utilization; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Likelihood Functions; Male; Medical Futility; Middle Aged; Odds Ratio; Survival Analysis; Ventricular Dysfunction, Left | 2004 |
[Inhibition of adenosine deaminase activity by drugs influencing the cardiovascular system].
Topics: Adenosine; Adenosine Deaminase Inhibitors; Animals; Aspirin; Cardiovascular Agents; Cardiovascular System; Deoxyadenosines; Female; Fibrinolytic Agents; Isoenzymes; Isosorbide Dinitrate; Male; Metoprolol; Molsidomine; Rabbits; Random Allocation; Simvastatin; Vasodilator Agents; Vasomotor System | 2004 |
Trends in the care of patients with acute myocardial infarction at a university-affiliated Veterans Affairs Medical Center.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arkansas; Aspirin; Cardiology Service, Hospital; Cardiovascular Agents; Drug Utilization Review; Female; Heparin, Low-Molecular-Weight; Hospitals, Teaching; Hospitals, Veterans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Patterns, Physicians'; Registries | 2005 |
Borderline coronary lesions may lead to serious coronary events--long-term outcome in 65 conservatively treated patients.
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Angiography; Coronary Disease; Coronary Stenosis; Death, Sudden, Cardiac; Female; Heart Conduction System; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Time Factors; Treatment Outcome | 2005 |
Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anemia; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cohort Studies; Comorbidity; Drug Utilization; Female; Fibrinolytic Agents; Glomerular Filtration Rate; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Kidney Failure, Chronic; Life Tables; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nova Scotia; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Smoking; Survival Analysis; Thrombolytic Therapy; Treatment Outcome | 2005 |
Carotid stenting.
Topics: Aged; Aspirin; Cardiovascular Agents; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Stents; Stroke; Ticlopidine | 2006 |
Changes in the use of cardiovascular medicines in the elderly aged 75 years or older--a population-based Kuopio 75+ study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cohort Studies; Digoxin; Diuretics; Drug Utilization; Finland; Homebound Persons; Humans; Hypertension; Institutionalization; Nitrates; Survivors; Time Factors; Warfarin | 2007 |
The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2007 |
Evidence-based use of medications in patients with coronary artery disease in a rural Australian community.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Cardiovascular Agents; Coronary Artery Disease; Drug Interactions; Evidence-Based Medicine; Female; Heart Failure; Hospitals, Rural; Hospitals, Teaching; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; New South Wales; Practice Patterns, Physicians'; Retrospective Studies; Rural Health Services | 2007 |
Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Artery Bypass; Coronary Artery Disease; Drug Prescriptions; Drug Utilization; Elective Surgical Procedures; England; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Discharge; Practice Patterns, Physicians'; Retrospective Studies; Secondary Prevention; Treatment Outcome | 2008 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
[Severe vasoespasm during coronary angiograms in a patient with Prinzmetal syndrome].
Topics: Administration, Cutaneous; Administration, Oral; Angina Pectoris, Variant; Aspirin; Cardiovascular Agents; Chest Pain; Coronary Angiography; Coronary Vasospasm; Diltiazem; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Humans; Male; Middle Aged; Nitrates; Platelet Aggregation Inhibitors; Time Factors | 2008 |
[Medical therapy in revascularized coronary artery disease patients].
Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; China; Coronary Artery Disease; Databases as Topic; Drug Utilization; Follow-Up Studies; Hospitals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged | 2008 |
Polypill for the treatment of cardiovascular diseases part 2. LC-MS/TOF characterization of interaction/degradation products of atenolol/lisinopril and aspirin, and mechanisms of formation thereof.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Cardiovascular Agents; Chromatography, Liquid; Drug Combinations; Drug Interactions; Lisinopril; Mass Spectrometry; Molecular Structure; Molecular Weight; Platelet Aggregation Inhibitors | 2008 |
Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Insurance, Pharmaceutical Services; Medicare; Models, Economic; Myocardial Infarction; Patient Compliance; Quality-Adjusted Life Years; Treatment Outcome; United States | 2008 |
Aspirin for prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans | 2008 |
News of the polypill.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors | 2008 |
Reflections on the regulation of the Polypill.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Approval; Drug Combinations; Europe; Folic Acid; Government Regulation; Health Policy; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Treatment Outcome | 2009 |
Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Agents; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Peptic Ulcer; Polypharmacy; Prospective Studies; Risk Factors | 2009 |
Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Artery Disease; Databases as Topic; Drug Administration Schedule; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Durapatite; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prosthesis Design; Registries; Sirolimus; Stainless Steel; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Durapatite; Hyperplasia; Lipids; Materials Testing; Models, Animal; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Stainless Steel; Surface Properties; Sus scrofa; Ticlopidine; Wound Healing | 2009 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Polymers; Prosthesis Design; Risk Assessment; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Myocardial perfusion imaging and cardiovascular outcomes in a cancer population.
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Cardiovascular Diseases; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Perfusion Imaging; Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Smoking; Stroke Volume; Time Factors; Ventricular Function, Left | 2009 |
Aspirin for primary prevention of vascular disease in people with diabetes.
Topics: Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Primary Prevention | 2009 |
Aspirin for the primary prevention of vascular events?
Topics: Adult; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Middle Aged; Primary Prevention; Randomized Controlled Trials as Topic; Risk Assessment | 2009 |
Medication underuse during long-term follow-up in patients with peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Agents; Drug Therapy, Combination; Evidence-Based Medicine; Female; Follow-Up Studies; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prognosis; Registries; Risk Factors | 2009 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Creatinine; Diabetes Mellitus; Drug-Eluting Stents; Follow-Up Studies; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Sirolimus; Stroke Volume; Ticlopidine | 2010 |
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Ticlopidine; Time Factors | 2011 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cilostazol; Disease Progression; Epoprostenol; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Quality of Life; Risk Assessment; Risk Factors; Severity of Illness Index; Societies, Medical; Tetrazoles; Time Factors; Treatment Outcome; Vascular Surgical Procedures; Vasodilator Agents | 2010 |
AAA- a further step towards a moratorium for aspirin in the primary prevention.
Topics: Aged; Ankle Brachial Index; Aspirin; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Primary Prevention; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Scotland; Time Factors; Treatment Outcome | 2010 |
Investigation of gastroduodenal mucosal injuries caused by low-dose aspirin therapy in patients with cerebral infarction.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Agents; Cerebral Infarction; Chi-Square Distribution; Duodenal Ulcer; Duodenoscopy; Duodenum; Female; Gastric Mucosa; Gastroscopy; Humans; Intestinal Mucosa; Japan; Male; Middle Aged; Prevalence; Prospective Studies; Stomach Ulcer | 2010 |
Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy: preliminary study.
Topics: Aged; Aspirin; Cardiovascular Agents; Duodenal Ulcer; Endoscopy, Digestive System; Esophageal Neoplasms; Esophagitis, Peptic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Japan; Male; Middle Aged; Pilot Projects; Severity of Illness Index; Stomach Neoplasms; Stomach Ulcer | 2010 |
Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Australia; Cardiovascular Agents; Coronary Artery Bypass; Drug Therapy, Combination; Europe; Evidence-Based Medicine; Female; Healthcare Disparities; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inpatients; Male; Middle Aged; Myocardial Revascularization; New Zealand; North America; Odds Ratio; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Risk Factors; Sex Factors; South America; Time Factors; Treatment Outcome | 2010 |
Racial and ethnic disparities in cardiovascular medication use among older adults in the United States.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Ethnicity; Female; Health Services Accessibility; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Racial Groups; Risk Factors; Socioeconomic Factors | 2010 |
Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Female; Heart Conduction System; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive Care Units; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Admission; Registries; Severity of Illness Index; Sweden | 2010 |
Primary prevention of myocardial infarction: putting the evidence to use.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Evidence-Based Medicine; Heart Conduction System; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Prevalence; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention | 2010 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Stenosis; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Republic of Korea; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
Topics: Aged; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Humans; Male; Middle Aged; Patient Selection; Peripheral Arterial Disease; Primary Prevention; Time Factors; Treatment Outcome | 2010 |
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Drug-Eluting Stents; Female; Genotype; Humans; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prosthesis Design; Sirolimus; Thrombectomy; Thrombosis; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2012 |
A national survey on aspirin patterns of use and persistence in community outpatients in Italy.
Topics: Adult; Aged; Ambulatory Care; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cross-Sectional Studies; Drug Prescriptions; Drug Utilization; Female; Guideline Adherence; Health Care Surveys; Humans; Inappropriate Prescribing; Italy; Logistic Models; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Practice Patterns, Physicians'; Preventive Health Services; Primary Health Care; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Young Adult | 2011 |
Peter Rothwell: a dedicated flouter of fashion.
Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Endarterectomy, Carotid; Fibrinolytic Agents; History, 20th Century; History, 21st Century; Humans; Ischemic Attack, Transient; Predictive Value of Tests; Prognosis; Stroke; United Kingdom | 2011 |
Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population.
Topics: Acute Disease; Adult; Aged; Aspirin; Baltimore; Cardiovascular Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Coronary Angiography; Coronary Artery Disease; Diagnostic Techniques, Cardiovascular; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Mass Screening; Middle Aged; Multivariate Analysis; Myocardial Revascularization; Odds Ratio; Predictive Value of Tests; Prospective Studies; Recurrence; Referral and Consultation; Research Design; Risk Assessment; Risk Factors; Time Factors; Tomography, X-Ray Computed; Unnecessary Procedures | 2011 |
Discontinuation of aspirin for secondary prevention.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Risk Factors; Secondary Prevention; Treatment Refusal | 2011 |
Drug discontinuation effects are part of the pharmacology of a drug.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Awards and Prizes; Cardiovascular Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Substance Withdrawal Syndrome | 2011 |
Killing two birds with one salicylate: aspirin's dual roles in preventative health.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anticarcinogenic Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Esophageal Neoplasms; Humans; Incidence; Lung Neoplasms; Neoplasms; Preventive Health Services; Risk Assessment; Risk Factors | 2011 |
On the potential contribution of aspirin to healthy ageing programmes.
Topics: Age Factors; Aging; Anticarcinogenic Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Health Status; Humans; Neoplasms; Primary Prevention; Risk Factors | 2016 |
Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary Prevention; Stroke | 2012 |
Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Cardiovascular Agents; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Restenosis; Drug Delivery Systems; Drug Therapy, Combination; Drug-Eluting Stents; Equipment Design; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2012 |
Gastric injury caused by low-dose aspirin therapy in consecutive Japanese patients: a prospective study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodies, Bacterial; Asian People; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Chi-Square Distribution; Female; Gastric Mucosa; Gastroscopy; Helicobacter pylori; Histamine H2 Antagonists; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prospective Studies; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Stomach Ulcer; Tablets, Enteric-Coated; Time Factors | 2012 |
Why P is not perfect.
Topics: Aspirin; Bayes Theorem; Cardiovascular Agents; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Complications; Evidence-Based Medicine; False Negative Reactions; False Positive Reactions; Humans; Meta-Analysis as Topic; Models, Statistical; Primary Prevention; Probability; Research Design; Risk Assessment; Sex Factors | 2012 |
Primary prevention with aspirin in type 2 diabetic patients. Searching for the right spot.
Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypertension; Male; Primary Prevention | 2012 |
Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care?
Topics: Anti-Bacterial Agents; Aspirin; Benchmarking; Cardiovascular Agents; Heart Failure; Hospital Administration; Hospital Mortality; Humans; Insurance Claim Review; Medicare Part A; Myocardial Infarction; Outcome and Process Assessment, Health Care; Pneumococcal Vaccines; Pneumonia; Quality Indicators, Health Care; Quality of Health Care; United States | 2008 |
Treatment and outcomes of acute coronary syndrome in the cancer population.
Topics: Academic Medical Centers; Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Myocardial Revascularization; Neoplasms; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Texas; Thrombolytic Therapy; Time Factors; Treatment Outcome | 2012 |
Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Attitude of Health Personnel; Awareness; Cardiovascular Agents; Chi-Square Distribution; China; Cytoprotection; Drug Prescriptions; Drug Utilization; Gastrointestinal Hemorrhage; Health Care Surveys; Health Knowledge, Attitudes, Practice; Histamine H2 Antagonists; Hospitals, University; Humans; Practice Patterns, Physicians'; Proton Pump Inhibitors; Retrospective Studies | 2012 |
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Cardiovascular Agents; Electrocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Risk Factors | 2012 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Mortality in patients with premature lower extremity atherosclerosis.
Topics: Academic Medical Centers; Adult; Age of Onset; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Comorbidity; Female; Humans; Kaplan-Meier Estimate; Lower Extremity; Male; Middle Aged; Multivariate Analysis; North Carolina; Peripheral Arterial Disease; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors | 2013 |
[Adverse effects of cardiovascular agents in Japan--update 2012].
Topics: Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Aspirin; Benzazepines; Cardiovascular Agents; Drug Combinations; Embolism; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Hypernatremia; Japan; Platelet Aggregation Inhibitors; Substance Withdrawal Syndrome; Tolvaptan | 2012 |
The role of aspirin in primary prevention of vascular events.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary Prevention; Stroke | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Disease-Free Survival; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Registries; Retrospective Studies; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus; Female; Guideline Adherence; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Renal Dialysis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction.
Topics: Aged; Apoptosis; Aspirin; Base Sequence; Cardiovascular Agents; Case-Control Studies; Cell Survival; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; CpG Islands; Cytoprotection; DNA Methylation; Dose-Response Relationship, Drug; Endocytosis; Endothelial Cells; Epigenesis, Genetic; Female; Fibroblast Growth Factor 2; Humans; Lipoproteins, LDL; Male; Middle Aged; Molecular Sequence Data; Myocardial Infarction; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Scavenger Receptors, Class E; Transfection; Up-Regulation | 2013 |
Primary prophylactic aspirin use and incident stroke: reasons for geographic and racial differences in stroke study.
Topics: Aged; Aged, 80 and over; Aspirin; Black or African American; Cardiovascular Agents; Chi-Square Distribution; Comorbidity; Female; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Primary Prevention; Propensity Score; Proportional Hazards Models; Residence Characteristics; Risk Factors; Stroke; United States; White People | 2013 |
Progression of asymptomatic carotid stenosis despite optimal medical therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Biomarkers; Cardiovascular Agents; Carotid Stenosis; Chi-Square Distribution; Cholesterol, LDL; Comorbidity; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Stroke; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex | 2013 |
The inhibitory effect of simvastatin and aspirin on histamine responsiveness in human vascular endothelial cells.
Topics: Actin Cytoskeleton; Actins; Antigens, CD; Aspirin; Cadherins; Calcium; Calcium Signaling; Cardiovascular Agents; Cell Shape; Cells, Cultured; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Histamine; Histamine Agonists; Histamine Antagonists; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phosphorylation; Receptors, Histamine H1; Simvastatin; Time Factors | 2014 |
Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance.
Topics: Adult; Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Community Health Services; Comorbidity; Delivery of Health Care; Female; Health Behavior; Health Care Surveys; Health Facilities; Health Knowledge, Attitudes, Practice; Healthcare Disparities; Humans; Male; Middle Aged; Quality Indicators, Health Care; Risk Assessment; Risk Factors; Surveys and Questionnaires; Urban Health Services; Washington | 2014 |
Modern clinical research: guidelines for the practicing clinician or source of confusion?
Topics: Aspirin; Biomedical Research; Cardiovascular Agents; Evidence-Based Medicine; Family Practice; Guidelines as Topic; Humans; Myocardial Infarction; Practice Patterns, Physicians'; Stroke; Uncertainty | 2013 |
Regular use of aspirin for cardiovascular disease prevention in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Female; Humans; Italy; Male; Middle Aged; Prevalence; Young Adult | 2014 |
Autonomic modulation in a patient with syncope and paroxysmal atrial-fibrillation.
Topics: Adult; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Follow-Up Studies; Heart Rate; Humans; Male; Physical Stimulation; Syncope; Treatment Outcome | 2014 |
Regarding "Progression of asymptomatic carotid stenosis despite optimal medical therapy".
Topics: Aspirin; Cardiovascular Agents; Carotid Stenosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors | 2014 |
Reply: To PMID 23806255.
Topics: Aspirin; Cardiovascular Agents; Carotid Stenosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors | 2014 |
Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Bypass; Databases, Factual; Drug Utilization; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Randomized Controlled Trials as Topic; Retrospective Studies; Secondary Prevention; Treatment Outcome | 2014 |
The natural history of asymptomatic severe carotid artery stenosis.
Topics: Aged; Aspirin; Asymptomatic Diseases; Blood Flow Velocity; Cardiovascular Agents; Carotid Stenosis; Chi-Square Distribution; Comorbidity; Disease Progression; Disease-Free Survival; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Registries; Retrospective Studies; Risk Factors; Severity of Illness Index; Stroke; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex | 2014 |
Simultaneous quantitation of aspirin, amlodipine and simvastatin in a fixed dose combination of encapsulated tablet formulation by HPLC-UV method.
Topics: Amlodipine; Aspirin; Cardiovascular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Combinations; Limit of Detection; Reproducibility of Results; Simvastatin; Spectrophotometry, Ultraviolet; Tablets; Technology, Pharmaceutical | 2014 |
[Special characteristics of progression of myocardial remodeling in patients with various forms of unstable angina].
Topics: Aged; Angina, Unstable; Aspirin; Benzopyrans; Cardiovascular Agents; Disease Progression; Drug Therapy, Combination; Echocardiography, Doppler; Ethanolamines; Female; Heart Failure; Humans; Male; Middle Aged; Nebivolol; Outcome Assessment, Health Care; Perindopril; Platelet Aggregation Inhibitors; Prognosis; Severity of Illness Index; Simvastatin; Time Factors; Ventricular Remodeling | 2014 |
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Artery Bypass; Coronary Artery Disease; Directive Counseling; Female; Guideline Adherence; Humans; Hypolipidemic Agents; Inpatients; Male; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Registries; Secondary Prevention; Smoking Cessation; United States | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Female; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recurrence; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; United States | 2015 |
Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-Dose Combination of Cardiovascular Drugs.
Topics: Administration, Cutaneous; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Aspirin; Atorvastatin; Cardiovascular Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Delivery Systems; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lisinopril; Microinjections; Platelet Aggregation Inhibitors; Swine | 2015 |
Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
Topics: Africa; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Developing Countries; Drug Costs; Health Services Accessibility; Healthcare Disparities; Humans; Poverty; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors | 2015 |
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Argentina; Aspirin; Bangladesh; Brazil; Canada; Cardiovascular Agents; Cardiovascular Diseases; Chile; China; Colombia; Developed Countries; Developing Countries; Drug Costs; Family Characteristics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Income; India; Iran; Malaysia; Pakistan; Pharmacies; Platelet Aggregation Inhibitors; Poland; Rural Population; Secondary Prevention; South Africa; Sweden; Turkey; United Arab Emirates; Urban Population; Zimbabwe | 2016 |
Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
Topics: Angiotensin II; Animals; Animals, Newborn; Aspirin; Atrial Natriuretic Factor; Calcineurin; Calcium; Calcium Signaling; Cardiovascular Agents; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypertrophy, Left Ventricular; Male; Mice; Myocytes, Cardiac; Myosin Heavy Chains; Natriuretic Peptide, Brain; NFATC Transcription Factors; Phosphorylation; Stroke Volume; Ventricular Function, Left | 2016 |
Association of increasing age with receipt of specialist care and long-term mortality in patients with non-ST elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiology; Cardiovascular Agents; Comorbidity; Delivery of Health Care; England; Female; General Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Referral and Consultation; Registries; Risk Factors; Secondary Prevention; Specialization; Time Factors; Treatment Outcome; Wales | 2016 |
Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice.
Topics: Administrative Claims, Healthcare; Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Utilization Review; Female; General Practice; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Ireland; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vasodilator Agents | 2016 |
Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer.
Topics: Aged; Aspirin; Biliary Tract Neoplasms; Cardiovascular Agents; Comorbidity; Disease Progression; Disease-Free Survival; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Multivariate Analysis; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
[Polypill for secondary coronary heart disease prevention].
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Medication Adherence; Ramipril | 2015 |
How to translate clinical trial results into gain in healthy life expectancy for individual patients.
Topics: Age Distribution; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Decision Support Techniques; Disease-Free Survival; Humans; Life Expectancy; Models, Statistical; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment | 2016 |
[Combination drug improves adherence].
Topics: Aspirin; Atorvastatin; Capsules; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2016 |
Optimizing prevention and guideline-concordant care in Montenegro.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clopidogrel; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Montenegro; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prospective Studies; Ticlopidine | 2016 |
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cardiovascular Agents; Disability Evaluation; Disease Progression; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Propensity Score; Registries; Remission Induction; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2016 |
Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Biomarkers; Blood Glucose; Blood Pressure; Brain Ischemia; Cardiovascular Agents; Chi-Square Distribution; Databases, Factual; Diffusion Magnetic Resonance Imaging; Disability Evaluation; Female; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Admission; Predictive Value of Tests; Protective Factors; Retrospective Studies; Risk Factors; Severity of Illness Index; Stroke | 2016 |
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Middle Aged; Primary Prevention; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Treatment Outcome | 2016 |
Effect of Long-Term, Low-Dose Aspirin Therapy on Renal Graft Function.
Topics: Adult; Aged; Aspirin; Biomarkers; Cardiovascular Agents; Creatinine; Female; Humans; Kidney; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2017 |
Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Netherlands; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Registries; Retrospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Combination cardiovascular drugs.
Topics: Aminobutyrates; Amlodipine; Aspirin; Biphenyl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Nebivolol; Omeprazole; Perindopril; Tetrazoles; Valsartan | 2017 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascular Agents; Cilostazol; Critical Illness; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Iloprost; Infusions, Intravenous; Ischemia; Limb Salvage; Lower Extremity; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Smoking; Smoking Cessation; Tetrazoles; Thromboangiitis Obliterans; Time Factors; Treatment Outcome; Vasodilator Agents | 2017 |
End-of-life prescribing of aspirin in patients with breast or colorectal cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Cancer Survivors; Cardiovascular Agents; Cardiovascular Diseases; Colorectal Neoplasms; Female; Humans; Male; Prospective Studies; Terminal Care | 2019 |
Nullification of aspirin induced gastrotoxicity and hepatotoxicity by prior administration of wheat germ oil in Mus musculus: histopathological, ultrastructural and molecular studies.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Agents; Catalase; Chemical and Drug Induced Liver Injury; Glutathione; Liver; Male; Malondialdehyde; Mice; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Plant Oils; Protective Agents; Stomach; Stomach Ulcer; Superoxide Dismutase | 2017 |
Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007-2015: A Serial, Cross-sectional Study.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Cross-Sectional Studies; Female; Guideline Adherence; Humans; Male; Middle Aged; Minnesota; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prevalence; Primary Health Care; Primary Prevention; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2017 |
The Effect of Monthly Medication on Mortality After a Coronary Event.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Retrospective Studies; Sex Factors; Survival Rate; Time Factors | 2018 |
Sex Differential in 15-Hydroxyprostaglandin Dehydrogenase Levels in the Lumen of Human Intracranial Aneurysms.
Topics: Adult; Aged; Aspirin; Biomarkers; Cardiovascular Agents; Embolization, Therapeutic; Female; Humans; Hydroxyprostaglandin Dehydrogenases; Intracranial Aneurysm; Male; Middle Aged; Sex Factors; Stents; Up-Regulation | 2017 |
Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Carrier Proteins; Contactins; Europe; Female; Gene Frequency; Genetic Markers; Genetic Predisposition to Disease; Genome-Wide Association Study; Haplotypes; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Phenotype; Polymorphism, Single Nucleotide; Primary Prevention; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Factors; RNA-Binding Proteins; Thromboxane A2; Thromboxane B2; Time Factors; White People | 2018 |
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Internal; Computed Tomography Angiography; Female; Fibromuscular Dysplasia; Humans; Hyperplasia; Neointima; Recurrence; Risk Factors; Stroke | 2018 |
Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers.
Topics: Aged; Algorithms; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Carotid Stenosis; Clinical Decision-Making; Complement C3; Computed Tomography Angiography; Databases, Factual; Decision Support Techniques; Endarterectomy, Carotid; Female; Fibrinogen; Humans; Inflammation Mediators; Male; Middle Aged; Predictive Value of Tests; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Color | 2018 |
Using extended theory of planned behavior to understand aspirin adherence in pregnant women.
Topics: Adaptation, Psychological; Adult; Aspirin; Cardiovascular Agents; Female; Health Knowledge, Attitudes, Practice; Humans; Hypertension, Pregnancy-Induced; Intention; Interpersonal Relations; Iran; Male; Medication Adherence; Middle Aged; Models, Psychological; Pregnancy; Prospective Studies; Psychological Theory; Risk Assessment; Risk Factors; Spouses | 2018 |
The ASPRE pre-eclampsia trial: implications for basic research and clinical practice.
Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Evidence-Based Medicine; Female; Humans; Pre-Eclampsia; Pregnancy; Protective Factors; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2018 |
The Beat Goes On: The Story of Five Ageless Cardiac Drugs.
Topics: Aspirin; Atropine; Cardiovascular Agents; Digitalis Glycosides; History, 15th Century; History, 16th Century; History, 17th Century; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; History, Medieval; Humans; Nitroglycerin; Quinidine | 2018 |
Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Diabetes Mellitus; Hemorrhage; Humans; Patient Selection; Primary Prevention; Protective Factors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2019 |
Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Practice Guidelines as Topic; Primary Prevention; Risk Assessment | 2019 |
[The Polypill - A Practicable Approach?]
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2019 |
Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Drug Prescriptions; Female; Follow-Up Studies; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Prescription Drugs; Prospective Studies; Registries; Secondary Prevention; ST Elevation Myocardial Infarction; Switzerland | 2020 |
Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Databases, Factual; Female; France; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Primary Prevention; Risk Factors; Secondary Prevention; Time Factors | 2020 |
Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Male; Pharmacies; Practice Patterns, Physicians'; Rural Health; Tablets; Urban Health | 2019 |
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Combined Modality Therapy; Drug Therapy, Combination; Elective Surgical Procedures; Female; Fibrinolytic Agents; Hemorrhage; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vitamin K | 2019 |
Treatment outcome of acute coronary syndrome patients admitted to Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia; A retrospective cross-sectional study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cross-Sectional Studies; Ethiopia; Female; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Secondary Prevention; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2020 |
Median Arcuate Ligament Syndrome With Celiac Artery Aneurysm and Dissection.
Topics: Aortic Dissection; Aspirin; Cardiovascular Agents; Celiac Artery; Conservative Treatment; Female; Humans; Median Arcuate Ligament Syndrome; Middle Aged; Treatment Outcome | 2020 |
Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; Italy; Male; Middle Aged; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Precision Medicine; Primary Prevention | 2021 |
Polypills - A Central Strategy for Improving Cardiovascular Health.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans | 2021 |
Potentially inappropriate prescriptions to Brazilian older people with Alzheimer disease: A cross-sectional study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspirin; Brazil; Cardiovascular Agents; Central Nervous System Agents; Clonazepam; Cross-Sectional Studies; Drug Interactions; Female; Humans; Inappropriate Prescribing; Male; Polypharmacy; Quetiapine Fumarate; Sertraline | 2021 |
Multicomponent spectrophotometric determination of a ternary mixture of widely-prescribed cardiovascular drugs by four different methods.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Humans; Ramipril; Spectrophotometry | 2023 |
One Pill for Everyone? Twenty Years of Polypill for Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors | 2023 |